Postoperative pain slows surgical recovery, impacting the return of normal function for weeks, months, or longer. Here we report the antihyperalgesic actions of a new compound, resolvin D1 (RvD1), known to reduce inflammation and to suppress pain after peripheral nerve injury, on the acute pain occurring after paw incision and the prolonged pain after skin-muscle retraction. Injection of RvD1 (20-40 ng) into the L5-L6 intrathecal space 30 minutes before surgery reduces the postincisional primary mechanical hypersensitivity, lowering the peak change by approximately 70% (with 40 ng) and reducing the area under the curve (AUC) for the entire 10-day postincisional course by approximately 60%. Intrathecal injection of RvD1 on postoperative day (POD) 1 reduces the hyperalgesia to the same level as that from preoperative injection within a few hours, an effect that persists for the remaining PODs. Tactile allodynia and hyperalgesia following the skin/muscle incision retraction procedure, measured at the maximum values 12 to 14 days, is totally prevented by intrathecal RvD1 (40 ng) given at POD 2. However, delaying the injection until POD 9 or POD 17 results in RvD1 causing only transient and incomplete reversal of hyperalgesia, lasting for <1 day. These findings demonstrate the potent, effective reduction of postoperative pain by intrathecal RvD1 given before or shortly after surgery. The much more limited effect of this compound on retraction-induced pain, when given 1 to 2 weeks later, suggests that the receptors or pathways for resolvins are more important in the early than the later stages of postoperative pain. Ó
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Postoperative pain slows surgical recovery, impacting the return of normal function for weeks, months, or longer. Here we report the antihyperalgesic actions of a new compound, resolvin D1 (RvD1), known to reduce inflammation and to suppress pain after peripheral nerve injury, on the acute pain occurring after paw incision and the prolonged pain after skin-muscle retraction. Injection of RvD1 (20-40 ng) into the L5-L6 intrathecal space 30 minutes before surgery reduces the postincisional primary mechanical hypersensitivity, lowering the peak change by approximately 70% (with 40 ng) and reducing the area under the curve (AUC) for the entire 10-day postincisional course by approximately 60%. Intrathecal injection of RvD1 on postoperative day (POD) 1 reduces the hyperalgesia to the same level as that from preoperative injection within a few hours, an effect that persists for the remaining PODs. Tactile allodynia and hyperalgesia following the skin/muscle incision retraction procedure, measured at the maximum values 12 to 14 days, is totally prevented by intrathecal RvD1 (40 ng) given at POD 2. However, delaying the injection until POD 9 or POD 17 results in RvD1 causing only transient and incomplete reversal of hyperalgesia, lasting for <1 day. These findings demonstrate the potent, effective reduction of postoperative pain by intrathecal RvD1 given before or shortly after surgery. The much more limited effect of this compound on retraction-induced pain, when given 1 to 2 weeks later, suggests that the receptors or pathways for resolvins are more important in the early than the later stages of postoperative pain.
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Introduction
Postoperative pain is an acute obstacle to rapid functional recovery and earlier hospital discharge after surgery. Furthermore, the incidence of ensuing chronic postoperative pain is substantial after certain procedures [32] . Surgery can also result in pain that only resolves over months, or persists longer, causing incapacitance and psychological stress for an extended time [24, 29] . For both medical and economic reasons, therefore, it is desirable to minimize postoperative pain.
Both peripheral and central factors contribute to postoperative pain [11, 33] . The initial discharge of local nerves caused by the incision [46] and the later, delayed activation of impulses from peripheral nerve that may be conducted by injured or uninjured fibers [4, 5, 17, 30] probably contribute to the establishment of longer-lasting hyperalgesia [28] , and there is little doubt that changes in the central nervous system (CNS), at least at the spinal cord (and probably also in the brain), are essential for the maintained chronic pain [10, 23, 24] . The differential ability of different drugs, applied at the incision site or delivered systemically, to prevent or reverse postoperative pain supports the concept of at least 2 stages of postoperative pain, an induction stage and a maintenance stage, which involve different mechanisms and occur at different locations [2, 12, 27] . Experiments with glutamate receptor antagonists delivered intrathecally around the time of skin incision show the importance of AMPA/kainate and mGluR5 receptors for the induction of postincisional pain [26, 31, 50] .
Resolvins are novel lipid mediators produced by cells of inflammatory exudates that stimulate resolution of inflammation [34] [35] [36] [37] . Resolvin D1 was first identified in resolving inflammatory exudates, murine brain and microglial cells [18, 22, 37] . Its complete stereochemistry was confirmed and assigned, as well as its potent anti-inflammatory and proresolving actions [34, 35] . Recent publications report an antihyperalgesic effect of resolvins in several different pain models. Resolvins D1 and E1 were shown to reduce pain after nerve injury or peripheral inflammation, through both 
